Worth reading
78Important
Scored from 3 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
982000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Monthly exercise status of the 10th Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
Who receives how much
Shares delivered during the target month: 982,000 new shares and 0 transferred treasury shares
EVO FUND (allottee of the 10th Series of Stock Acquisition Rights)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
Exercise ratio subject to the exercise restriction: 10.0% (982,000 shares delivered across all series / 9,828,500 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
The exercise price during June 2026 ranged from ¥114 to ¥119. Details of the adjustment clause and the adjustment floor: not disclosed
Number of Stock Acquisition Rights
Total issued: 82,700 rights; exercised during the target month: 9,820 rights; unexercised at the end of the month preceding the target month: 59,980 rights; unexercised at the end of the target month: 50,160 rights
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
13 February 2026: Issuance of the 10th Series of Stock Acquisition Rights (with exercise price adjustment clause) allotted to EVO FUND (total issued: 82,700 rights)
| Item | Details |
|---|---|
| Type of issuance or disposal | Monthly exercise status of the 10th Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Shares delivered during the target month: 982,000 new shares and 0 transferred treasury shares |
| Intended allottee | EVO FUND (allottee of the 10th Series of Stock Acquisition Rights) |
| Dilution Rate | Exercise ratio subject to the exercise restriction: 10.0% (982,000 shares delivered across all series / 9,828,500 listed shares as of the payment date for the issuance) |
| Total number of issued shares | 12,100,500 shares (as of the end of the month preceding the target month, including 20 treasury shares) → Not disclosed |
| Exercise price | The exercise price during June 2026 ranged from ¥114 to ¥119. Details of the adjustment clause and the adjustment floor: not disclosed |
| Number of Stock Acquisition Rights | Total issued: 82,700 rights; exercised during the target month: 9,820 rights; unexercised at the end of the month preceding the target month: 59,980 rights; unexercised at the end of the target month: 50,160 rights |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | 13 February 2026: Issuance of the 10th Series of Stock Acquisition Rights (with exercise price adjustment clause) allotted to EVO FUND (total issued: 82,700 rights) |
Items this document does not state (19)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status for June 2026.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.